Cui et al., identified TLN1 as a poor-prognostic biomarker in AML and showed that this gene may be related to the resistance of austocystin-D and few other drugs in AML cells (Cui et al., 2022). The gene discussed is TLN1; the disease is acute myeloid leukemia.